Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed ...

Medicine & Health - Diseases, Conditions, Syndromes

Jan 21, 2009 not rated yet 0